Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting

Journal of Medical Economics

Volumn 21, Issue 5, 2018, Pages 497-509

  Chakravarty, Abhiroop ^a   Rastogi, Mohini ^a   Dhankhar, Praveen ^b   Bell, Kelly F ^c  

^a Complete HEOR Solutions ^*  (India)

^b Formerly AstraZeneca ^*  (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

cost effectiveness; dapagliflozin; economic benefits; Short term; type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; HEMOGLOBIN A1C; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ARTICLE; BODY WEIGHT; BODY WEIGHT GAIN; BODY WEIGHT LOSS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL OUTCOME; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; ECONOMIC MODEL; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; MEDICAL CARE; NETWORK META-ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG EFFECT; ECONOMICS; HEALTH CARE PLANNING; STATISTICS AND NUMERICAL DATA; UNITED NATIONS; UNITED STATES; UTILIZATION;

BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; BODY WEIGHT; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HEALTH EXPENDITURES; HEALTH RESOURCES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; QUALITY-ADJUSTED LIFE YEARS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; UNITED NATIONS; UNITED STATES;

EID: 85042906055     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.1080/13696998.2018.1434182     Document Type: Article

References (45)

1. Global report on diabetes. Geneva: World Health Organization; 2016. http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf
2. CDC Diabetes Report Card United States. Atlanta, GA: CDC; 2014. https://www.cdc.gov/diabetes/pdfs/library/diabetesreportcard2014.pdf
3. Classification and diagnosis of diabetes. American Diabetes Association 2015;38(Supp1):S8-S16. http://care.diabetesjournals.org/content/diacare/38/Supplement_1/S8.full.pdf
4. Economic costs of diabetes in the U.S. in 2012. American Diabetes Association 2013;36:1033-1046. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609540/pdf/1033.pdf
5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm–2017 Executive Summary. American Association of Clinical Endocrinologists 2017;23:207-38
6. ADA. Standards of medical care in diabetes - 2017. Diabetes Care 2017;40(Supp1):S1-S135.
7. Seufert J., SGLT2 inhibitors–an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Synd Obesity Target Ther 2015;8:543-54
8. Mikhail N., Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes. World J Diabetes 2014;5:854-9
9. Ferrannini E, Ramos S, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise. A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24
10. Bailey C, Morales VE, Woo V, et al. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabetic Med 2014;32:531-41
11. Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2013;15:432-40
12. Monami M, Nardini C, Mannucci E., Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;16:457-66
13. Bailey C, Iqbal N, T’joen C, et al. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 2012;14:951-9
14. Henry R, Murray A, Marmolejo M, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012;66:446-56
15. List J, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7
16. Charokopou M, McEwan P, Lister S, et al. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic Med 2015;32:890-8
17. Davies M, Chubb B, Smith I, et al. Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabetic Med 2011;29:313-20
18. Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008:43-55
19. Cummins E, Scott N, Rothnie K, et al. Dapagliflozin for the treatment of type 2 diabetes. UK: Aberdeen HTA Group, 2012
20. Erhardt W, Bergenheim K, Duprat-Lomon I, et al. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metfomiin in the treatment of type 2 diabetes mellitus in Germany. Clin Drug Invetig 2012;32:189-202
21. ®) in type 2 diabetes in Sweden. Primary Care Diabetes 2012;6:127-36
22. Mezquita R, Pérez A, Ramírez de Arellano A, et al. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diabetes Ther 2013;4:417-30
23. ®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes 2015;9:39-47
24. Tzanetakos C, Melidonis A, Verras C, et al. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Serv Res 2014;14:1-13
25. Barnett A, Orme M, Fenici P, et al. Systematic review and network meta-analysis to compare dapagliflozin with other diabetes medications in combination with metformin for adults with type 2 diabetes. Intern Med 2014;S6-S006
26. Aagren M, Luo W., Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States. J Med Econ 2011;14:108-14
27. Kulchaitanaroaj P, Brooks J, Ardery G, et al. Incremental costs associated with physician and pharmacist collaboration to improve blood pressure control. Pharmacotherapy 2012;32:772-80
28. Quilliam B, Simeone J, Ozbay A, et al. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care 2011;17:673-80
29. Yu A, Wu E, Birnbaum H, et al. Short-term economic impactof body weight change among patients with type 2 diabetes treated with antidiabetic agents; analysis using claims, laboratory and medical record data. Curr Med Res Opin 2007;23:2157-69
30. Analy$ource online; New York, US: AnalySource; 2016. https://www.analysource.com/
31. Vijan S, Sussman J, Yudkin J, et al. Effects of patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med 2014;174:1227-34
32. Matza L, Boye K, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65
33. Timbie J, Hayward R, Vijan S., Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med 2010;170:1037-44
34. Currie C, Morgan C, Poole C, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
35. Charokopou M, McEwan P, Lister S, et al. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the treatment of type 2 diabetes mellitus from a UK healthcare system perspective. BMC Health Serv Res 2015;15:1-11
36. Orme M, Fenici P, Lomon I, et al. A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy. Diabetol Metab Synd 2014;6:1-13
37. Wilding J, Bailey C, Rigney U, et al. Dapagliflozin therapy for type 2 diabetes in primary care: changes in HbA1c, weight and blood pressure over 2 years follow-up. Prim Care Diabetes 2017;11:437-44
38. Grandy S, Hashemi M, Langkilde AM, et al. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab 2014;16:645-50
39. FDA US. FDA label for Farxiga (Dapagliflozin). US 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202293s003lbl.pdf
40. FDA US. FDA label for INVOKANA (Canagliflozin). US 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204042s026lbl.pdf
41. Amos T, Montejano L, Juneau P, et al. Healthcare costs of urinary tract infections and genital mycotic infections among patients with type 2 diabetes mellitus initiated on canagliflozin: a retrospective cohort study. J Med Econ 2016;20:303-13
42. FDA US. FDA label for Liraglutide. US 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf
43. Wang B, Roth J, Nguyen H, et al. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States. PLoS One 2015;10:1-13
44. OECD. Stat: Organization for Economic Co-operation and Development. France: OECD.http://stats.oecd.org/Index.aspx?querytype=view&queryname =221
45. XE. Canada. http://www.xe.com/currencytables/?from=USD&date=2015-07-01